Gene or Genome – Page 5

Gilead Sciences Prepares for Summer 2025 Launch of Long-Acting HIV Prevention Drug Lenacapavir

2 months ago talkbio0Tagged Approved, Clinical Trials, Gilead Sciences, HIV Prevention, HIV sales, Lenacapavir, PREP gene, PURPOSE studies, United States Food and Drug Administration

Gilead Sciences, lenacapavir, HIV prevention, PrEP, long-acting injectable, FDA approval, HIV sales, clinical trials, PURPOSE studies

AnaptysBio’s Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial

2 months ago talkbio0Tagged Agonist, AnaptysBio, Autoimmune Diseases, Immunoregulation, PDCD1 gene, Rheumatoid Arthritis, Rosnilimab

Rosnilimab, PD-1 agonist, rheumatoid arthritis, Phase 2b trial, immune modulation, AnaptysBio, autoimmune disease

Illumina’s Double-Edged Sword: Navigating US-China Trade Tensions

3 months ago talkbio0Tagged BIOSECURE, China, DNA Sequence, Entity, Illumina, Industry, Tension, TNFRSF19 gene, unreliable

Illumina, China, tariffs, trade tensions, DNA sequencing, unreliable entity list, biotech industry, BIOSECURE Act

Battle for HIV PrEP Market: Gilead’s Twice-Yearly Injection Challenges GSK’s Apretude

3 months ago talkbio0Tagged Apretude, HIV Prevention, Lenacapavir, long-acting injectables, PREP gene, SmithKline Beecham, ViiV Healthcare

HIV prevention, PrEP, lenacapavir, Apretude, long-acting injectables, Gilead Sciences, GSK, ViiV Healthcare

X4 Pharmaceuticals Restructures to Advance Mavorixafor for Chronic Neutropenia and Optimize XOLREMDI Promotion

3 months ago talkbio0Tagged Antagonist muscle action, Chronic neutropenia, CXCR4 gene, strategic, WHIM syndrome, Xolremdi

X4 Pharmaceuticals, mavorixafor, XOLREMDI, CXCR4 antagonist, WHIM syndrome, chronic neutropenia, workforce reduction, strategic restructuring

Kura Oncology’s Ziftomenib Achieves Phase 2 Success in AML, Paving Way for Dual-Track Phase 3 Program

3 months ago talkbio0Tagged AML, Breakthrough Therapy, DNA Sequence Rearrangement, Identifier, KMT2A gene, KOMET-001, KOMET-017, Leukemia, Myelocytic, Acute, Menin Inhibitor, Mutation, NPM1, NPM1 gene, Phase 3 trials, Ziftomenib

Ziftomenib, Acute Myeloid Leukemia (AML), NPM1 mutation, KMT2A rearrangement, Phase 3 trials, KOMET-001, KOMET-017, Menin inhibitor, Breakthrough Therapy Designation

NFL Legend Jerome Bettis Joins CDC Foundation’s “Live to the Beat” Campaign to Tackle Heart Health in Black Community

3 months ago talkbio0Tagged beat, Bettis, Black Populations, Cardiovascular Diseases, Centers for Disease Control and Prevention (U.S.), Community, Foundations, heart health, Hypertensive disease, Jerome, NEFL gene

Jerome Bettis, CDC Foundation, Live to the Beat, cardiovascular disease, Black community, hypertension, heart health, NFL

Pharmaceutical Industry Warns of Drug Shortages and Price Hikes Due to Trump’s New Tariffs

3 months ago talkbio0Tagged Active, APIs, chain disruption, Drug Industry, Drug shortages, Groups, Increased, Prices, TNFRSF19 gene, Trump tariffs

Trump tariffs, drug shortages, price increases, pharmaceutical industry, trade groups, supply chain disruption, generic drugs, active pharmaceutical ingredients (APIs)